Prikaz osnovnih podataka o dokumentu
Structural myocardial alterations in diabetes and hypertension: the role of galectin-3
dc.creator | Seferović, Jelena | |
dc.creator | Lalić, Nebojša M. | |
dc.creator | Floridi, Federico | |
dc.creator | Tesić, Milorad | |
dc.creator | Seferović, Petar M. | |
dc.creator | Giga, Vojislav | |
dc.creator | Lalić, Katarina | |
dc.creator | Jotić, Aleksandra | |
dc.creator | Jovičić, Snežana | |
dc.creator | Colak, Emina | |
dc.creator | Salerno, Gerardo | |
dc.creator | Cardelli, Patrizia | |
dc.creator | Di Somma, Salvatore | |
dc.date.accessioned | 2019-09-02T11:38:23Z | |
dc.date.available | 2019-09-02T11:38:23Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 1434-6621 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/2074 | |
dc.description.abstract | Background: Galectin-3 is a protein widely distributed in the heart, brain and blood vessels, and has a regulatory role in inflammation, immunology and cancer. Many studies demonstrated that the increased level of galectin-3 is associated with progressive fibrosis and stiffening of the myocardium. The aim of this study was to investigate the role of galectin-3 in patients with type 2 diabetes (T2D) and/or arterial hypertension (HT). Methods: Study population included 189 patients, with no coronary artery disease, divided into three groups: group 1 (T2D), group 2 (T2D+HT), and group 3 (HT). All subjects underwent routine laboratory tests, as well as specific biomarkers assessment [galectin-3, glycosylated hemoglobin (HbA(1c)), N- terminal fragment B-type natriuretic peptide (NT-proBNP)]. Cardiological evaluation included physical examination, transthoracic tissue Doppler echocardiography and stress echocardiography. Results: The results of this study demonstrated significantly increased levels of galectin-3, blood glucose, and HbA(1c) in group 2. Also, echocardiographicaly, left ventricular (LV) diameters and IVS thickness were increased in this group of patients. Furthermore, in the same cohort a positive correlation between galectin-3 and NT-pro BNP, and galectin-3 and LV mass were demonstrated. In addition, a negative correlation between galectin-3 and LV end-diastolic diameter was revealed. Conclusions: This study revealed that levels of galectin-3 were higher in patients with both T2D and HT, and correlated with LV mass, indicating the potential role of this biomarker for early detection of myocardial structural and functional alterations. | en |
dc.publisher | Walter de Gruyter Gmbh, Berlin | |
dc.rights | restrictedAccess | |
dc.source | Clinical Chemistry and Laboratory Medicine | |
dc.subject | galectin-3 | en |
dc.subject | hypertension | en |
dc.subject | myocardial fibrosis | en |
dc.subject | type 2 diabetes | en |
dc.title | Structural myocardial alterations in diabetes and hypertension: the role of galectin-3 | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Гига, Војислав; Ди Сомма, Салваторе; Салерно, Герардо; Царделли, Патризиа; Јотић, Aлександра; Цолак, Емина; Сеферовић, Петар М.; Флориди, Федерицо; Лалић, Катарина; Лалић, Небојша М.; Јовичић, Снежана; Сеферовић, Јелена; Тесић, Милорад; | |
dc.citation.volume | 52 | |
dc.citation.issue | 10 | |
dc.citation.spage | 1499 | |
dc.citation.epage | 1505 | |
dc.citation.other | 52(10): 1499-1505 | |
dc.citation.rank | M21 | |
dc.identifier.wos | 000341683500017 | |
dc.identifier.doi | 10.1515/cclm-2014-0265 | |
dc.identifier.pmid | 24887961 | |
dc.identifier.scopus | 2-s2.0-84921353607 | |
dc.type.version | publishedVersion |